Literature DB >> 19259810

Altered platelet monoamine oxidase-B activity in idiopathic Parkinson's disease.

Maroof Husain1, Rakesh Shukla, Madhu Dikshit, Pradeep K Maheshwari, Devika Nag, Rikhab C Srimal, Prahlad K Seth, Vinay K Khanna.   

Abstract

A case-control study was undertaken to investigate the status of platelet monoamine oxidase-B (MAO-B) activity in Indian cases of idiopathic Parkinson's disease. A significant increase in the activity of platelet MAO-B was observed in Parkinson's cases (n = 26) as compared to controls (n = 26). No significant change in the activity of the enzyme was observed while the data was analysed with respect to age, sex and duration of disease. A trend of decrease in platelet MAO-B activity was observed in Parkinson's cases with respect to stage although the change was not significant. No correlation in platelet MAO-B activity was observed with respect to age and sex in the control subjects. Parkinson's cases treated with L-DOPA and MAO-B inhibitor exhibited decreased platelet MAO-B activity as compared to drug naive cases and those treated with L-DOPA alone. Interestingly, Parkinson's cases treated with L-DOPA and amantadine also had lower platelet MAO-B activity as compared to drug naive cases and those treated with L-DOPA alone. Activity of platelet MAO-B in Parkinson's patients was increased in naive cases and those treated with L-DOPA alone or in combination with other drugs compared to controls. The results of the present study indicate that phenotypic activity of platelet MAO-B is high in Indian Parkinson's cases. Further, action mechanism of drugs used in the treatment of Parkinson's disease could be understood by assay of platelet MAO-B activity. It is an interesting observation and may be looked further in large number of cases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19259810     DOI: 10.1007/s11064-009-9929-4

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  59 in total

1.  Monoamine oxidase activity in blood platelets of migraine patients.

Authors:  M M Caramona; M D Cotrim; C F Ribeiro; T Macedo
Journal:  J Neural Transm Suppl       Date:  1990

Review 2.  Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.

Authors:  Jack J Chen; David M Swope; Khashayar Dashtipour
Journal:  Clin Ther       Date:  2007-09       Impact factor: 3.393

3.  Reduced monoamine oxidase activity in blood platelets from schizophrenic patients.

Authors:  D L Murphy; R J Wyatt
Journal:  Nature       Date:  1972-07-28       Impact factor: 49.962

4.  Effects of agricultural work and other proxy-derived case-control data on Parkinson's disease risk estimates.

Authors:  K M Semchuk; E J Love
Journal:  Am J Epidemiol       Date:  1995-04-15       Impact factor: 4.897

5.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

6.  Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy.

Authors:  D H Lee; M Mendoza; M T Dvorozniak; E Chung; M H van Woert; M D Yahr
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1989

7.  MAOB intron 13 and COMT codon 158 polymorphisms, cigarette smoking, and the risk of PD.

Authors:  M A Hernán; H Checkoway; R O'Brien; P Costa-Mallen; I De Vivo; G A Colditz; D J Hunter; K T Kelsey; A Ascherio
Journal:  Neurology       Date:  2002-05-14       Impact factor: 9.910

8.  Association of a monoamine oxidase B allele with Parkinson's disease.

Authors:  J H Kurth; M C Kurth; S E Poduslo; J D Schwankhaus
Journal:  Ann Neurol       Date:  1993-04       Impact factor: 10.422

9.  Assignment of genes for human monoamine oxidases A and B to the X chromosome.

Authors:  L M Kochersperger; E L Parker; M Siciliano; G J Darlington; R M Denney
Journal:  J Neurosci Res       Date:  1986       Impact factor: 4.164

Review 10.  Oxidative stress, glutamate, and neurodegenerative disorders.

Authors:  J T Coyle; P Puttfarcken
Journal:  Science       Date:  1993-10-29       Impact factor: 47.728

View more
  2 in total

Review 1.  Platelets in Neurodegenerative Conditions-Friend or Foe?

Authors:  Odette Leiter; Tara L Walker
Journal:  Front Immunol       Date:  2020-05-05       Impact factor: 7.561

Review 2.  Beyond Haemostasis and Thrombosis: Platelets in Depression and Its Co-Morbidities.

Authors:  Benedetta Izzi; Alfonsina Tirozzi; Chiara Cerletti; Maria Benedetta Donati; Giovanni de Gaetano; Marc F Hoylaerts; Licia Iacoviello; Alessandro Gialluisi
Journal:  Int J Mol Sci       Date:  2020-11-21       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.